SEES
Light Combination Therapy
SEES is our novel approach to treating intermediate age-related macular degeneration (AMD). This technique uses innovative light therapy to counteract the damaging effects of AMD and promote tissue health, which can help to retain vision.
Currently, validation clinical trials are ongoing to evaluate the potential of SEES further. We’ll keep you updated with the latest developments!
Clinical Need
AMD is a leading cause of irreversible visual impairment and blindness globally, particularly affecting individuals over the age of 601.
Over
200M
people are impacted by neovascular age-related macular degeneration (AMD), which ranks among the most prevalent causes of blindness2.
Over
10%
of persons with early-stage Dry AMD will progress to the more severe forms of the disease, leading to significant vision loss3.
SEES Stands Out
Multi-mode light stimulation of the retina
SEES employs advanced light technologies, including lasers to stimulate the eye through the promotion of retina-tissue homeostasis.
Standardized Therapeutic Parameters
SEES aims to achieve consistent and effective treatment outcomes thanks to standardized and specific procedure parameters.
Dosimetry
SEES allows the operator to evaluate retina tissue response to light stimulation in real-time and decide to modify and apply tailored therapeutic dosimetry to personalise the intervention to each patient’s need.
Compact and Intuitive Design
SEES is designed to guarantee patient comfort and clinician ease of use.
At Oculox, we are fully aware that, the quality of a solution will also be measured through the required delivery procedures and the related user experience.
Non-Invasive
SEES is a treatment method that focuses on minimizing the discomfort and burden experienced by patients, while also ensuring efficient delivery of treatment. The proposed light therapy sessions last for less than 2 minutes, which makes them extremely fast. Furthermore, the optical arrangement is designed to be contactless, except for the chinrest. This means that patients can receive treatment without any physical contact, making the process even more comfortable and convenient for them.
Real-time retina alignment monitoring
SEES therapeutic console provides ultra-fast alignment feedback for safe and homogeneous treatment sessions, optimizing patient care and outcomes.
References
- Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009;102(2):56-61.
- Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus. 2022;14(9):e29583.
- Gehrs K, A., et al. Age-related macular degeneration–emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.
Policies
Oculox Technologies SA
Via Industria 3
CH-6933 Muzzano
Switzerland